Summary & Overview
HCPCS J2320: Nandrolone Decanoate Injection, up to 50 mg
HCPCS Level II code J2320 denotes an intramuscular injection of nandrolone decanoate, up to 50 mg per administration. This code captures billing for a specific anabolic steroid preparation used in therapeutic contexts where nandrolone decanoate is indicated. Nationally, accurate coding for injectable medications like J2320 matters for clinical documentation, payer medical policy alignment, and consistent claims processing.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of reimbursement benchmarking and coverage considerations across major payers, plus clinical context about the service type and typical sites of care. The publication outlines common billing practices, reporting expectations for a single-dose injectable medication, and where to look for payer policy and medical necessity guidance.
This analysis is intended for revenue cycle, coding, and clinical staff seeking a concise reference for HCPCS Level II code J2320. It highlights what the code represents, how it is typically used in outpatient and ambulatory settings, and the areas where payers commonly apply utilization review and prior authorization policies. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2320 represents an injection of nandrolone decanoate, dosed up to 50 mg per administration. The service is an therapeutic intramuscular medication administration intended to deliver an anabolic–androgenic steroid formulation.
Service type: Medication injection / therapeutic drug administration
Typical site of service: Outpatient clinic, physician office, or other ambulatory care settings where intramuscular injections are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J2320 (injection, nandrolone decanoate, up to 50 mg) is an adult male or female with documented cachexia, severe weight loss related to chronic illness, or hypogonadism where anabolic steroid therapy is clinically indicated and prescribed by an authorized provider. The patient often presents to an outpatient infusion clinic, ambulatory surgical center, or physician office for intramuscular administration. The clinical workflow includes: initial evaluation by a physician (history, physical exam, medication review), verification of indication and informed consent, review of allergies and coagulation status, preparation of the correct dose of nandrolone decanoate, administration via deep intramuscular injection (typically gluteal muscle), monitoring for immediate adverse reactions for 15–30 minutes, documentation of lot number and manufacturer, and scheduling follow-up for efficacy and safety monitoring (testosterone levels if applicable, liver function tests, lipid profile). Common payors involved in prior authorization and coverage determinations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare. The service is typically provided in outpatient settings: physician office, clinic, or ambulatory infusion center; inpatient administration is uncommon but possible when part of complex inpatient care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |